Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT3 | Q9NTG7 | 7/20 | 0.70 |
| ▸ | KDM5A | P29375 | 7/20 | 0.70 |
| ▸ | THRA | P10827 | 3/20 | 0.70 |
| ▸ | THRB | P10828 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.70 |
| ▸ | KDM7A | Q6ZMT4 | 2/20 | 0.70 |
| ▸ | MLNR | O43193 | 1/20 | 0.70 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.70 |
| ▸ | PHF2 | O75151 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | FYN | P06241 | 1/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Budiodarone SCHEMBL29380098 | 1.00 | SIRT3 (0.70) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Budiodarone SCHEMBL1946428 | 1.00 | SIRT3 (0.70) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Budiodarone SCHEMBL1946426 | 1.00 | SIRT3 (0.70) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Budiodarone SCHEMBL30517707 | 0.95 | SIRT3 (0.64) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| SCHEMBL25808724 | 0.95 | KDM5A (0.63) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| SCHEMBL14192203 | 0.94 | SIRT3 (0.62) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Hydrochloric Acid SCHEMBL7583295 | 0.93 | ALDH1A1 (0.62) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| SCHEMBL3128930 | 0.93 | SIRT3 (0.61) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| SCHEMBL3128944 | 0.93 | SIRT3 (0.61) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| SCHEMBL3128785 | 0.92 | SIRT3 (0.69) | SIRT3KDM5ATHRATHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145881-A1 | Antiarrhythmic precursor compounds, methods of synthesis and methods of use | Aryx Therapeutics, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2145881-A1 | Antiarrhythmic precursor compounds, methods of synthesis and methods of use | Aryx Therapeutics, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-1904502-B1 | ANTIARRHYTHMIC PRECURSOR COMPOUNDS, METHODS OF SYNTHESIS AND METHODS OF USE | ARYX THERAPEUTICS INC (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-1904502-B1 | ANTIARRHYTHMIC PRECURSOR COMPOUNDS, METHODS OF SYNTHESIS AND METHODS OF USE | ARYX THERAPEUTICS INC (US) | 2009-10-21 | — | — | EP | disclosed |
| US-7498449-B2 | Antiarrhythmic precursor compounds, methods of synthesis and methods of use | ARYX THERAPEUTICS (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498449-B2 | Antiarrhythmic precursor compounds, methods of synthesis and methods of use | ARYX THERAPEUTICS (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498449-B2 | Antiarrhythmic precursor compounds, methods of synthesis and methods of use | ARYX THERAPEUTICS (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080114059-A1 | Novel Compounds For Treatment of Cardiac Arrhythmia and Methods of Use | ARYX THERAPEUTICS, INC. | 2008-05-15 | — | — | US | disclosed |
| US-20080114059-A1 | Novel Compounds For Treatment of Cardiac Arrhythmia and Methods of Use | ARYX THERAPEUTICS, INC. | 2008-05-15 | — | — | US | disclosed |
| US-7351842-B2 | )-{3-[4-(2-Ethylamino-ethoxy)-3,5-diiodo-benzoyl]-benzofuran-2-yl}-acetic acid sec-butyl ester; amiodarone derivatives; congestive heart failure, ischemic cardiomyopathy, atrial fibrillation, ventricular tachycardia; side effect reduction: pharmacolkinetics, oral bioavailability, nontoxic | ARYX THERAPEUTICS, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351842-B2 | )-{3-[4-(2-Ethylamino-ethoxy)-3,5-diiodo-benzoyl]-benzofuran-2-yl}-acetic acid sec-butyl ester; amiodarone derivatives; congestive heart failure, ischemic cardiomyopathy, atrial fibrillation, ventricular tachycardia; side effect reduction: pharmacolkinetics, oral bioavailability, nontoxic | ARYX THERAPEUTICS, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070060640-A1 | Antiarrhythmic Precursor Compounds, Methods Of Synthesis And Methods Of Use | ARYX THERAPEUTICS (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060640-A1 | Antiarrhythmic Precursor Compounds, Methods Of Synthesis And Methods Of Use | ARYX THERAPEUTICS (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060640-A1 | Antiarrhythmic Precursor Compounds, Methods Of Synthesis And Methods Of Use | ARYX THERAPEUTICS (US) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060640-A1 | Antiarrhythmic Precursor Compounds, Methods Of Synthesis And Methods Of Use | SCN11A, SCN10A, CYP4F11 | SIRT3 850/4885KDM5A 3772/4885THRA 535/4885 |
| US-20080114059-A1 | Novel Compounds For Treatment of Cardiac Arrhythmia and Methods of Use | TNNI3, TNNT2, RYR2 | SIRT3 520/4885KDM5A 3583/4885THRA 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.